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ess: diot@med.univ-touSummary A new anticholinergic aerosol containing 0.5mg ipratropium bromide
dissolved in 1mL of solution has been produced with the purpose of decreasing
nebulization time for patients compared to the traditional formulation which is
twice as voluminal (0.5mg/2mL, Boehringer-Ingelheim, France). The aim of this
study was to compare aerosol characteristics (inhaled mass, particle size distribution
and nebulization time) of these two formulations of ipratropium bromide, nebulized
alone and with terbutaline (5mg/2mL, Astra Zeneca, Sweden), to determine
whether the new formulation was equivalent to the old one. Four different jet
nebulizers were used: PariLC+s, Atomisor NL9Ms, Sidestreams and Mistynebs.
Statistical analysis of the results showed that for all types of nebulizer, the inhaled
mass of ipratropium bromide 0.5mg/1mL was significantly lower than the inhaled
mass of ipratropium bromide 0.5mg/2mL, and that there was no statistical
difference between the inhaled mass of ipratropium bromide 0.5mg/1mL+terbuta-
line 5mg/2mL and the inhaled mass of ipratropium bromide 0.5mg/2mL+terbuta-
line 5mg/2mL. The study also showed that the new formulation of ipratropium
bromide (0.5mg/1mL) mixed with terbutaline allowed a 26% decrease in
nebulization time compared to the old formulation (0.5mg/2mL) mixed withElsevier Ltd. All rights reserved.
8, Faculte´ de Me´decine, 2 bis Bld Tonnelle´, 37032 Tours Cedex, F-37000 France.
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distribution). This leads to the conclusion that a 2mL minimum volume is required
for nebulization, and that nebulization of ipratropium bromide 0.5mg/1mL alone
must be avoided.
& 2006 Elsevier Ltd. All rights reserved.Introduction
An aerosolized medication is designed to be
delivered in ventilated gas through the airways.
This mode of administration is particularly suitable
for treating respiratory disorders, as it allows the
drug to enter the respiratory tract directly. As a
consequence, doses required to obtain therapeutic
effects are lower than for oral administration.1
Aerosols can be produced by different techni-
ques, classified into three main categories: nebu-
lizers (jet, ultrasonic, and vibrating mesh),
metered dose inhalers and dry powder inhalers.
Compared to metered dose inhalers and dry powder
inhalers, nebulizers deliver high-drug doses with an
aerosol deposition targeted at the desired site of
action (i.e. pulmonary region).2 However, nebuli-
zers require preparation prior to treatment and
treatment time is longer.
Decreasing nebulization time would be of con-
siderable value for aerosol therapy, as it might
contribute to improved long-term compliance.
This study, based on the hypothesis that decreas-
ing the volume to be nebulized would decrease the
nebulization time, was designed to investigate to
what extent decreasing drug volume may affect
treatment efficiency.
A new formulation of ipratropium bromide
(Atrovents 0.5mg/1mL, Boehringer-Ingelheim,
France) containing 0.5mg of ipratropium bromide
in 1mL of solution was compared to the traditional
formulation (Atrovents 0.5mg/2mL, Boehringer-
Ingelheim, France) containing 0.5mg of ipratro-
pium bromide in 2mL of solution. This new
formulation is therefore twice as concentrated
with half the volume.
The aerosols produced with the two different
ipratropium bromide formulations, nebulized alone
and with terbutaline (Bricanyls 5mg/2mL, Astra
Zeneca, Sweden) were characterized using four
different jet nebulizers (PariLC+s, Atomisor
NL9Ms, Sidestreams, Mistynebs). This study was
focused on jet nebulizers only, as vibrating mesh
nebulizers are not suitable for hospital use, and
ultrasonic nebulizers have a residual volume which
is too large for nebulization of volumes as small as
1mL.Aerosol characteristics were measured in terms
of inhaled mass (ipratropium bromide and terbuta-
line) and particle size distribution. The inhaled
mass represents the quantity of drug actually
delivered by a given nebulizer for a defined
breathing pattern and period of time,3 i.e. the
quantity of drug which is not lost in the nebulizer
and can enter any region of the respiratory tract.
This parameter characterizes the efficiency of the
nebulization. The particle size distribution of the
aerosol gives a precise idea of the deposition sites
in the respiratory tract. It is characterized by the
volume mean diameter (VMD), which is the dia-
meter dividing the mass of aerosol into two equal
halves, and the percentage of droplets with
diameters between 1 and 5 mm, which corresponds
to the respiratory fraction, i.e. the particles
reaching the lungs.4 The nebulization time for each
formulation was also recorded. Statistical analysis
of the data was carried out to determine the
effects of the new formulation on aerosol char-
acteristics. The study should determine whether
this new formulation, which was originally devel-
oped to be prescribed alone, is equivalent to the
old one, in which case its aerosol characteristics
would be good enough to be prescribed alone, or if
it should be mixed with terbutaline for an
acceptable efficiency.Materials and methods
Jet nebulizers
Four kinds of jet nebulizer were tested: Side-
streams nebulizer with Portanebs compressor
(Medic-Aid, UK), PariLC+s nebulizer with Turbo
Boy Ns compressor (Pari, Germany), Atomisor
NL9Ms nebulizer with Atomisor Abox+s compres-
sor (Atomisor, DTF, France) and Mistynebs nebuli-
zer (Allegiance, France) with an air flow of 8 L/min
(compressed air).
Since a given model of nebulizer can have
significant performance variations from one unit
to the other,5 three nebulizers of each model were
tested, twice each, for each drug formulation.
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Four different drug formulations were tested:
ipratropium bromide (0.5mg/1mL) alone, ipratro-
pium bromide (0.5mg/2mL) alone, ipratropium
bromide (0.5mg/1mL) mixed with terbutaline
(5mg/2mL) and ipratropium bromide (0.5mg/
2mL) mixed with terbutaline (5mg/2mL). Thus,
96 experiments were performed to test inhaled
mass, with 96 additional experiments to test
particle size distribution (four kinds of nebulizer,
with three nebulizers of each kind tested twice
each for the four drug formulations, totaling 96
experiments).
The osmolarities of ipratropium bromide
(0.5mg/2mL) and ipratropium bromide (0.5mg/
1mL) have been measured with an automatic
osmometer (Hermann Roebling, Germany), and
equaled respectively 317 and 329milliosmol. Thus
the new formulation maintained a similar os-
molarity.Inhaled mass
The inhaled mass of ipratropium bromide and
terbutaline were measured, simulating patient
breathing using a respiratory pump and collecting
the aerosol on a filter. The nebulizer was connected
to its associated compressor. An absolute filter (A/
E, Gelman, Ann Arbor, MI) was positioned between
the nebulizer and the respiratory pump (Harvard
Apparatus, Ealing, UK) which was regulated accord-
ing to the European Standard EN 13544-16:
15 breaths/min, 500mL, I/E ¼ 1, as shown in
Fig. 1. The drug was introduced into the nebulizer.
The respiratory pump was turned on, followed by
the compressor. The total nebulization time,Respiratory pump
Compressor
Filter
Nebulizer
Figure 1 Experimental set-up to measure inhaled mass.
The air produced by the compressor nebulizes the drug
contained in the nebulizer; the respiratory pump
simulates patient breathing; the aerosol collected on
the filter is defined as the inhaled mass.defined by the end of spluttering, was recorded.
At the end of nebulization, the filter was folded and
put into a tube (T420, Simport, Canada). Forty
milliliter of solvent (1/1 0.001M hydrochloric acid
and pure methanol) were added and the filter was
ground. The tube was first centrifuged at 4000 rpm
for 10min at 13 1C (Eppendorf Centrifuge 5810R),
and the supernatant was centrifuged again at
14000 rpm for 5min at 13 1C (Eppendorf Centrifuge
5810R). The amount of active drug contained in the
supernatant was measured by high performance
liquid chromatography (HPLC) for ipratropium
bromide and ultraviolet (UV) spectrophotometry
for terbutaline.
Ipratropium bromide measurement by HPLC
The HPLC system consisted of a model 600 E
delivery pump, a model Wisp 717 automatic sample
injection device, a 2487 dual wavelength ultravio-
let UV spectrophotometer detector, and a 996
photodiode array detector coupled to the UV
detector outlet (all Waters, Saint Quentin en
Yvelynes, France). Analytic runs were processed
by the Millenium PC software system (Waters). The
mobile phase was composed of 1000mL buffer
solution (pH 3.2) plus 290mL acetonitrile. The
buffer solution was prepared by dissolving 2.51 g
heptanesulphonic acid sodium salt monohydrate in
1000mL water with pH adjusted to 3.2 with 0.05M
orthophosphoric acid. The flow rate was 1.5mL/
min and the UV detector was set to 210 nm. The
photodiode array detector was used to check for
peak purity.
Calibration curves were constructed from known
amounts of ipratropium bromide nebulized on
filters to obtain a linear relationship between the
amount of ipratropium bromide nebulized on the
filters and the area of the peaks. This relationship
was used to calculate the amount of ipratropium
bromide contained in the supernatants obtained
from the various experiments, following injection
of 40 mL of the supernatants.
Terbutaline measurement by UV
spectrophotometry
The UV spectrophotometer (Perkin Elmer, Lamb-
da20, USA) was calibrated to obtain a linear
relationship between absorbance at 243 nm and
the amount of terbutaline: precise amounts of
terbutaline (2, 1, 0.2, 0.1, 0.02mg) were deposited
on filters (A/E, Gelman, Ann Arbor, MI) which were
folded, put inside tubes (T420, Simport, Canada),
ground in 20mL of solvent (1/1 pure methanol and
0.001M hydrochloric acid) and centrifuged as
described above, then the supernatants were
tested using the UV spectrophotometer at 243 nm,
ARTICLE IN PRESS
C. Majoral et al.240blank being made from the solvent alone. Terbuta-
line mass contained in the supernatants obtained
from the various experiments was determined from
this linear relationship.Nebulization time
The total nebulization time was measured with a
chronometer from the beginning of nebulization
(compressor turned on) until the end of spluttering.Particle size distribution
Particle size distribution was measured with a laser
diffraction method (Mastersizer-X, Malvern, UK), as
shown in Fig. 2.7
The mouthpiece exit of the nebulizer was placed
close enough (1 cm) to the lens to avoid vignetting
(loss of light due to scattering at wide angles), and
far enough (2 cm) from the laser beam to avoid the
mouthpiece interfering with the expanded laser
beam, and the aerosol was directed towards the
laser beam without producing measurement arte-
fact.8 The aerosol passed through the laser beam
and was directed towards an extraction pump
(40 L/min) placed 5 cm from the laser beam.
The drug formulation was introduced into the
nebulizer. The extraction pump and the compressor
were turned on. At the end of nebulization, data
acquisition was stopped, and the compressor was
turned off.
The dispersion code was ‘‘polydisperse’’ and
optic presentation ‘‘2QAA’’. Data inversion calcula-
tions9,10 to determine Volume Mean Diameter
(VMD) and respiratory fractions, here defined as
the percentage of particles with diameters be-
tween 1 and 5 mm which is a reflection of how the2 cm
EXTRACTION
(40L/MIN)
1 cm
NEBULIZER
MOUTHPIECE
LASER
DETECTOR
5 cm
AEROSOL LENS
Figure 2 Laser diffraction method (Mastersizer-X, Mal-
vern, UK) to measure aerosol particle size distribution.
The aerosol passes through the laser beam and is directed
towards an extraction pump; data acquisition is carried
out instantly.aerosol may deposit in the bronchial tree,4 were
carried out using Mastersizer-X software.
Statistical analysis of the results
Statistical methods adapted to small samples were
applied to the results to highlight the potential
significant differences between the different drug
formulations and nebulizers tested: Exact Kruskal–Wallis tests of Monte Carlo were
performed to test the differences between the
four formulations for one nebulizer, and be-
tween the four nebulizers for one formulation. Exact permutation tests were performed to test
the differences between the two formulations of
ipratropium bromide alone and between the two
formulations of ipratropium bromide mixed with
terbutaline for each nebulizer. Wilcoxon signed exact rank tests were per-
formed to test the differences between terbuta-
line and ipratropium bromide inhaled mass for
the two formulations of ipratropium bromide
mixed with terbutaline for all the nebulizers
taken together.
These statistical tests were performed using the
StatXact software (version 3.0.2, Cytel Software
Corporation).
Results were expressed in medians and the
ranges in quartiles on the figures. A P value inferior
to 0.05 was considered as a significant difference.Results
Inhaled mass
Ipratropium bromide
Ipratropium bromide inhaled mass results were
expressed in terms of mass of ipratropium bromide
and are presented in Fig. 3 for ipratropium bromide
nebulized alone and mixed with terbutaline.
The results differed significantly between the
four formulations whatever the nebulizer:
P ¼ 0.001 for Sidestreams nebulizer, P ¼ 0.001
for PariLC+s nebulizer, P ¼ 0.028 for NL9Ms
nebulizer and P ¼ 0.001 for Mistynebs nebulizer.
Comparison of the samples (Fig. 3) indicated that
ipratropium bromide 0.5mg/1mL was responsible
for this statistical difference.
This was confirmed by the exact Kruskal–Wallis
tests of Monte Carlo performed to test the
differences between ipratropium bromide 0.5mg/
2mL, ipratropium bromide 0.5mg/1mL+terbutaline
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Figure 3 Ipratropium bromide inhaled mass when nebulized alone and mixed with terbutaline (n ¼ 6). Results
expressed in medians and ranges in quartiles. ‘‘’’ represents a significant difference between the samples (Po0.05).
‘‘NS’’ represents no significant difference between the samples.
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2mL+terbutaline 5mg/2mL, which showed that
there were no statistical differences between these
three formulations: P ¼ 0.482 for Sidestreams
nebulizer, P ¼ 0.993 for PariLC+s nebulizer,
P ¼ 0.740 for NL9Ms nebulizer and P ¼ 0.869 for
Mistynebs nebulizer.
Finally, there was a statistical difference be-
tween the two formulations of ipratropium bromide
alone (P ¼ 0.004 for Sidestreams nebulizer,
P ¼ 0.002 for PariLC+s nebulizer, P ¼ 0.041 for
NL9Ms nebulizer and P ¼ 0.002 for Mistynebs
nebulizer), and there was no statistical difference
between the two formulations of ipratropium
bromide mixed with terbutaline (P ¼ 0.582 for
Sidestreams nebulizer, P ¼ 0.857 for PariLC+s
nebulizer, P ¼ 0.389 for NL9Ms nebulizer and
P ¼ 0.910 for Mistynebs nebulizer), indicating that
ipratropium bromide 0.5mg/1mL should be mixed
with terbutaline for nebulization.
The results of the four nebulizers were statisti-
cally different for the two formulations of ipra-
tropium bromide alone (P ¼ 0.0002 for ipratropium
bromide 0.5mg/1mL and P ¼ 0.0162 for ipratro-
pium bromide 0.5mg/2mL) but not when used with
the two formulations of ipratropium bromide mixed
with terbutaline (P ¼ 0.2535 for ipratropium bro-
mide 0.5mg/1mL+terbutaline 5mg/2mL andP ¼ 0.0720 for ipratropium bromide 0.5mg/
2mL+terbutaline 5mg/2mL).Terbutaline
Terbutaline inhaled mass was also measured. The
results showed that terbutaline and ipratropium
bromide behaved similarly i.e. the mass fraction of
terbutaline inhaled mass was the same as the mass
fraction of ipratropium bromide inhaled mass when
these two drugs were mixed together: Wilcoxon
signed exact rank tests gave P ¼ 0.65 between
terbutaline and ipratropium bromide inhaled mass
for ipratropium bromide 0.5mg/1mL+terbutaline
5mg/2mL, and P ¼ 0.75 between terbutaline and
ipratropium bromide inhaled mass for ipratropium
bromide 0.5mg/2mL+terbutaline 5mg/2mL for all
the nebulizers taken together. This result was
confirmed by Exact Pearson Tests which gave a
correlation of 89% (P ¼ 0.004) for ipratropium
bromide 0.5mg/1mL+terbutaline 5mg/2mL, and
72% (P ¼ 0.01) for ipratropium bromide 0.5mg/
2mL+terbutaline 5mg/2mL.Nebulization time
Nebulization times for ipratropium bromide alone
and mixed with terbutaline are shown in Fig. 4.
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C. Majoral et al.242As expected, the fill volume influenced signifi-
cantly nebulization time for all the formulations of
ipratropium bromide alone and mixed with terbuta-
line (Po0.0001 for all the nebulizers).
The results of the four nebulizers were not
statistically different in terms of nebulization time
whatever the drug formulation: P ¼ 0.0757 for
ipratropium bromide 0.5mg/1mL, P ¼ 0.6872 for
ipratropium bromide 0.5mg/2mL, P ¼ 0.3554 for
ipratropium bromide 0.5mg/1mL+terbutaline
5mg/2mL and P ¼ 0.0867 for ipratropium bromide
0.5mg/2mL+terbutaline 5mg/2mL.The nebulization time had a strong linear regres-
sion with nebulization volume for all the nebulizers,
as shown by the following linear regression equations
(x ¼ nebulization volume (mL), y ¼ nebulization
time (min)): y ¼ 2.42x–0.29 (R2 ¼ 0.93, n ¼ 24) for
Sidestreams nebulizer, y ¼ 2.43x–0.99 (R2 ¼ 0.89,
n ¼ 24) for PariLC+s nebulizer, y ¼ 2.56x–0.59
(R2 ¼ 0.83, n ¼ 24) for NL9Ms nebulizer and
y ¼ 2.34x–0.53 (R2 ¼ 0.94, n ¼ 24) for Mistynebs
nebulizer. Fig. 5 shows an example of this linear
regression on the graph of Mistynebs nebulizer.Particle size distribution
Particle size distribution results were expressed
in terms of VMD (Fig. 6) and respiratory fractions
(Fig. 7).
In terms of VMD, there were no significant
differences between ipratropium bromide 0.5mg/
1mL and ipratropium bromide 0.5mg/2mL for any
nebulizer: P ¼ 0.552 for Sidestreams nebulizer,
P ¼ 1.000 for PariLC+s nebulizer, P ¼ 0.416 for
NL9Ms nebulizer and P ¼ 0.507 for Mistynebs
nebulizer. Neither were there significant differ-
ences between ipratropium bromide 0.5mg/
1mL+terbutaline 5mg/2mL and ipratropium
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P ¼ 1.000 for Sidestreams nebulizer, P ¼ 0.827
for PariLC+s nebulizer, P ¼ 0.152 for NL9Ms
nebulizer and P ¼ 0.485 for Mistynebs nebulizer.
Therefore, the admixture of terbutaline with
ipratropium bromide did not change aerosol dro-
plets size compared to ipratropium bromide neb-
ulized alone.
The results were not significantly different in
terms of respiratory fractions between the four
formulations for any of the nebulizers: P ¼ 0.858
for Sidestreams nebulizer, P ¼ 0.476 for PariLC+s
nebulizer, P ¼ 0.125 for NL9Ms nebulizer and
P ¼ 0.178 for Mistynebs nebulizer.
However, the results were significantly different
between the four nebulizers both in terms of VMD
and respiratory fractions for all the formulations of
ipratropium bromide alone and those mixed with
terbutaline: Po0.0001.Discussion
The objective of this study was to compare the new
ipratropium bromide formulation (0.5mg/1mL),
which reduces the volume to be nebulized, with
the traditional formulation (ipratropium bromide
0.5mg/2mL) when it is nebulized alone or mixed
with terbutaline, in terms of inhaled mass, neb-
ulization time and particle size distribution.
Ipratropium bromide alone and the admixture of
terbutaline with ipratropium bromide had the same
mass fraction of terbutaline and ipratropium
bromide inhaled mass, and the same aerosol
characteristics (particle size distribution). This
may be due to the fact that both solutions
have similar viscosities: 0.9923 103 Poiseuilles
(1.439 107 lbf s/in2) for ipratropium bromide and
1.0087 103 Poiseuilles (1.463 107 lbf s/in2) for
terbutaline.11
The inhaled mass of this new ipratropium
bromide formulation (0.5mg/1mL) is significantly
lower than the inhaled mass of ipratropium
bromide 0.5mg/2mL, ipratropium bromide
0.5mg/1mL+terbutaline 5mg/2mL and ipratro-
pium bromide 0.5mg/2mL+terbutaline 5mg/2mL.
Thus, nebulization of ipratropium bromide 0.5mg/
1mL alone cannot be recommended. In clinical
practice, ipratropium bromide (anticholinergic)
and terbutaline (b-agonist) are often administered
simultaneously, as mixing these two bronchodilator
classes may result in improving their efficiency,
particularly in chronic obstructive pulmonary dis-
ease (COPD)12 or in asthma.13 Anticholinergic
agents act as bronchodilators by blocking vagal
bronchomotor activity. They have a relatively sloweffect at onset, starting at around 10min, with the
peak effect occurring about 30–90min after inhala-
tion. b-Agonists are short-acting agents that pro-
duce bronchodilation within 3–5min, reaching a
peak at 15–30min.12 Combination therapy of
ipratropium and terbutaline with conventional
doses has been shown to produce a significantly
greater effect on forced expiratory volume in 1 s
(FEV1) than ipratropium alone in obstructive lung
diseases.14 This combination also leads to signifi-
cant changes in functional residual capacity (FRC)
in asthmatic children.13
The new formulation of ipratropium bromide
(0.5mg/1mL) mixed with terbutaline allowed a
26% decrease of nebulization time compared to the
old formulation (0.5mg/2mL) mixed with terbuta-
line without changing aerosol characteristics (in-
haled mass and particle size distribution). The new
ipratropium bromide formulation (0.5mg/1mL),
mixed with terbutaline, therefore allows nebuliza-
tion time to be decreased while keeping the same
inhaled mass, compared to the old 0.5mg/2mL
formulation mixed with terbutaline, and poten-
tially leads to improved clinical efficiency. Its major
advantage of reducing nebulization time is also its
major concern in clinical practice, since 1mL is not
recommended.
Statistical analysis of the results between the
different nebulizers tested showed that particle
size distributions (VMD and respiratory fractions)
were significantly different between the four
nebulizers for a single formulation, whereas they
were similar with all the ipratropium bromide
formulations for a single nebulizer. This indicates
that the device used can strongly affect aerosol
characteristics and therefore drug efficiency,
whereas the ipratropium bromide formulation
administered has no effect on the aerosol char-
acteristics.
Factors influencing the total dose delivered to a
patient’s airways include the initial volume fill, the
efficiency with which the nebulized aerosol is made
available for patient inhalation, and the amount of
residual volume left in the nebulizer on cessation of
the operation. This residual volume is typically
1mL, but may be as low as 0.5mL or as high as
1.5mL. The amount left is therefore not negligible
compared to a typical volume fill (e.g. 2.5mL).
Thus, treatment time becomes critically dependent
not only on the rate of aerosol inhaled mass and
volume fill, but also on the minimum volume a
nebulizer system requires to operate.15
This study shows that initial volumes of 2, 3 and
4mL containing the same amount of drug produced
similar inhaled mass with the four nebulizers
tested, whereas a fill volume of 1mL resulted in
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nebulizers tested require a minimum volume of
2mL but that increasing the volume to above 2mL
does not result in a better inhaled mass.
Other nebulizers with higher residual volumes
than those tested in this study require more than
2mL of drug to achieve an inhaled mass of about
25%. In particular, ultrasonic nebulizers are char-
acterized by residual volumes ranging from 0.8 to
2mL.16 These nebulizers have been demonstrated
to be more efficient with increasing drug formula-
tion volume.
On the other hand, new nebulizers which allow
low residual volume, such as Aerogen’s OnQTM
Aerosol Generator, could be used to nebulize
volumes smaller than 2mL with the same efficiency
in terms of inhaled mass as higher volumes,16 but
they are not readily available in hospital settings in
which disposable materials are preferred.
Decreasing the fill volume allows shorter neb-
ulization time for the patient, but it is unclear
whether the duration of nebulization has an impact
on the respiratory tract deposition efficiency. The
results obtained in terms of inhaled mass are
similar for 2, 3 and 4mL of ipratropium bromide
formulations, but they may not reflect patient
response exactly. A patient having an asthma
attack may breathe better after a few minutes
than at the very beginning of the nebulization,
which would mean that a minimum nebulization
duration is required. In this case, continuous
nebulization therapy could be considered as a
possible alternative until the patient is stable.17
On the other hand, a more concentrated solution
may produce a faster response from the patient. A
high volume of nebulized drug could lead to a larger
clearance and consequently more drug loss.
Thus, it could be of interest to carry out in vivo
deposition imaging in patients’ respiratory airways
while inhaling 2, 3 and 4mL of drug containing the
same amount of active drug, to verify whether the
results obtained in this study (i.e. equivalent
inhaled mass for 2, 3 and 4mL) would be similar
for in vivo experiments.Acknowledgements
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